BIONTECH SE |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 88.15 USD | -0.38% |
|
+1.90% | -16.58% |
| Apr. 23 | BIONTECH : Gets a Neutral rating from Deutsche Bank | ZD |
| Apr. 15 | Global markets live: Goldman Sachs, Apple, Salesforce, Boeing Tesla... |  |
Presenter SpeechRyan Richardson (Executives)Good afternoon, good morning. My name is Ryan Rich...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Calendar
2024-05-05
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
19
Last Close Price
82.7
EUR
Average target price
106.5
EUR
Spread / Average Target
+28.79%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -16.58% | 21.33B | |
| -1.79% | 105B | |
| +3.33% | 97.5B | |
| +1.86% | 22.19B | |
| -8.49% | 18.68B | |
| -42.33% | 16.6B | |
| -20.78% | 14.52B | |
| +5.05% | 14.09B | |
| +22.51% | 10.99B | |
| -23.94% | 8.63B |
- Stock Market
- Equities
- BNTX Stock
- News BioNTech SE
- Transcript : BioNTech SE - Special Call
